Back to News
Market Impact: 0.2
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsCompany Fundamentals
Niagen Bioscience reported Q3 2026 net sales of $27.2 million, including $23.3 million from Tru Niagen, and a net loss of $1.2 million. Basic and diluted loss per share were both $0.01; the article text is truncated before further results are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.10
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook